A Bioequivalence Study of Sunitinib Malate Capsules in Healthy Volunteers Under Fed Condition.
Latest Information Update: 12 Apr 2023
At a glance
- Drugs Sunitinib (Primary)
- Indications Alveolar soft part sarcoma; Bladder cancer; Gastrointestinal stromal tumours; Neuroendocrine tumours; Oesophageal cancer; Pancreatic cancer; Phaeochromocytoma; Prostate cancer; Renal cell carcinoma; Soft tissue sarcoma; Thyroid cancer; Uveal melanoma
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 07 Apr 2023 New trial record